EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors by Vasconcelos, Pedro E.N.S., Gergis, Carol, Viray, Hollis, Varkaris, Andreas, Fujii, Masanori, Rangachari, Deepa, VanderLaan, Paul A., Kobayashi, Ikei S., Kobayashi, Susumu S., Costa, Daniel B.

Get full text

Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: a single center analy... by DiStasio, Marcello, MD, PhD, Chen, Yigu, MPH, Rangachari, Deepa, MD, Costa, Daniel B., MD, PhD, Heher, Yael K., MD, MPH, VanderLaan, Paul A., MD, PhD

Get full text

EGFR testing in advanced non-small-cell lung cancer, a mini-review by Sheikine, Yuri, MD, PhD, Rangachari, Deepa, MD, McDonald, Danielle C., NP, Huberman, Mark S., MD, Folch, Erik S., MD, MSc, VanderLaan, Paul A., MD, PhD, Costa, Daniel B., MD, PhD

Get full text

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer by Piper-Vallillo, Andrew J., Halbert, Brian T., Rangachari, Deepa, Kobayashi, Susumu S., Costa, Daniel B.

Get full text

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience by Piper-Vallillo, A.J., Rotow, Julia K., Aredo, Jacqueline V., Shaverdashvili, Khvaramze, Luo, Jia, Carlisle, Jennifer W., Husain, Hatim, Muzikansky, Alona, Heist, Rebecca S., Rangachari, Deepa, Ramalingam, Suresh S., Wakelee, Heather A., Yu, Helena A., Sequist, Lecia V., Bauml, Joshua M., Neal, Joel W., Piotrowska, Zofia

Get full text

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors by Kobayashi, Ikei S., Shaffer, William, Viray, Hollis, Rangachari, Deepa, VanderLaan, Paul A., Kobayashi, Susumu S., Costa, Daniel B.

Get full text

Massive Thymic Hyperplasia Masquerading as Cancer: A Case Report and Review of the Literature by Gatof, Emily Stern, Jassim, Sarmad H., Ahn, Leah, Chen, Zsu-Zsu, VanderLaan, Paul A., Rangachari, Deepa

Get full text

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene by Schoepflin, Zachary R., Academia, Emmeline, Osataphan, Soravis A., Rangachari, Deepa, Sharifi, Sheida, VanderLaan, Paul A., Costa, Daniel B.

Get full text

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC by Ricciuti, Biagio, Naqash, Abdul Rafeh, Naidoo, Jarushka, Sehgal, Kartik, Miller, Adam, Kehl, Kenneth, Venkatraman, Deepti, Sands, Jacob, Lamberti, Giuseppe, Recondo, Gonzalo, Zhang, Jiajia, Macherla, Shravanti, Baig, Sameer, Walker, Paul, Rangachari, Deepa, Gainor, Justin F., Costa, Daniel B., Rizvi, Naiyer, Sholl, Lynette M., Nishino, Mizuki, Henick, Brian, Farago, Anna F., Awad, Mark M.

Get full text